Table 4 Clinicopathologic characteristics of patients according to sarcosine metabolism type
Parameter | Total N =721 (%) | High sarcosine type n = 36 (%) | Intermediate sarcosine type n = 21 (%) | Low sarcosine type n = 219 (%) | Null type n = 445 (%) | P-value |
|---|---|---|---|---|---|---|
Age (years) | Â | Â | Â | Â | Â | 0.200 |
  ≤50 | 428 (59.4) | 26 (72.2) | 13 (61.9) | 120 (54.8) | 269 (60.4) |  |
  >50 | 293 (40.6) | 10 (27.8) | 8 (38.1) | 99 (45.2) | 176 (39.6) |  |
Histologic grade | Â | Â | Â | Â | Â | 0.351 |
  I/II | 485 (67.3) | 29 (80.6) | 13 (61.9) | 147 (67.1) | 296 (66.5) |  |
  III | 236 (32.7) | 7 (19.4) | 8 (38.1) | 72 (32.9) | 149 (33.5) |  |
Tumor stage | Â | Â | Â | Â | Â | 0.082 |
  T1 | 355 (49.2) | 12 (33.3) | 10 (47.6) | 120 (54.8) | 213 (47.9) |  |
  T2/T3 | 366 (50.8) | 24 (66.7) | 11 (52.4) | 99 (45.2) | 232 (52.1) |  |
Nodal metastasis | Â | Â | Â | Â | Â | 0.799 |
  Absent | 427 (59.2) | 22 (61.1) | 14 (66.7) | 125 (57.1) | 266 (59.8) |  |
  Present | 294 (40.8) | 14 (38.9) | 7 (33.3) | 94 (42.9) | 179 (40.2) |  |
Estrogen receptor status | Â | Â | Â | Â | Â | 0.049 |
  Negative | 259 (35.9) | 9 (25.0) | 3 (14.3) | 75 (34.2) | 172 (38.7) |  |
  Positive | 462 (64.1) | 27 (75.0) | 18 (85.7) | 144 (65.8) | 273 (61.3) |  |
Progesterone receptor status | Â | Â | Â | Â | Â | 0.011 |
  Negative | 347 (48.1) | 13 (36.1) | 4 (19.0) | 102 (46.6) | 228 (51.2) |  |
  Positive | 374 (51.9) | 23 (63.9) | 17 (81.0) | 117 (53.4) | 217 (48.8) |  |
HER-2 status | Â | Â | Â | Â | Â | 0.072 |
  Negative | 565 (78.4) | 24 (66.7) | 17 (81.0) | 163 (74.4) | 361 (81.1) |  |
  Positive | 156 (21.6) | 12 (33.3) | 4 (19.0) | 56 (25.6) | 84 (18.9) |  |
Ki-67 LI (%) | Â | Â | Â | Â | Â | 0.007 |
  ≤14 | 409 (56.7) | 21 (58.3) | 17 (81.0) | 138 (63.0) | 233 (52.4) |  |
  >14 | 312 (43.3) | 15 (41.7) | 4 (19.0) | 81 (37.0) | 212 (47.6) |  |
Tumor recurrence | 63 (8.7) | 8 (22.2) | 1 (4.8) | 15 (6.8) | 39 (8.8) | 0.022 |
No. of patient deaths | 61 (8.5) | 5 (13.9) | 1 (4.8) | 20 (9.1) | 35 (7.9) | 0.558 |